Our test menu has expanded, again! This month, we have added 11 new Spotlight™ panels, three new Focus™ panels, and one new Comprehensive panel, across multiple disorder types.
This month, we are happy to announce we have added another 11 tests to our growing catalog of Courtagen Spotlight™ Panels. These small (3 to 50 genes) panels provide clinicians with a targeted approach to genetic testing, and are best used when a patient's symptomatology is discernible. Each Spotlight Panel contains addresses a group of disorders with overlapping symptoms, making test selection clear and straightforward.
We are happy to announce the addition of 10 new tests to our Spotlight™ Panel line, which provides clinicians a targeted approach to genetic testing when a patient's symptomatology is discernible. Each Spotlight Panel contains between approximately 3 to 50 genes selected to address a group of disorders with overlapping symptoms, making test selection clear and straightforward.
We are excited to announce that we received a Notice of Allowance from the United States Patent and Trademark Office for a patent that uses a personalized medicine approach to match genetic markers for chronic pain with therapeutic drugs, including the cannabis-derived compound cannabidiol.
We are happy to announce that we have added 17 new gene panels to our Spotlight line of tests. These new tests will expand our menu by 65%, offering new testing options in neurology, endocrinology, epilepsy, developmental delay, mitochondrial disease, and other disease areas.
At Courtagen, we offer DNA testing that uses next generation sequencing to diagnose neurological, mitochondrial, and other disorders. Because the brain and mitochondria are so complex, many of our panels have a thousand genes or more.
After performing diagnostic testing on several thousand patients with seizure disorders, Courtagen's Clinical Team has described a variant in the ALG13 gene that directly causes infantile spasms, intellectual disability, and severe neurologic disease.